source
- Roivant’s inhaled pulmonary hypertension drug mosliciguat shows strong Phase 2 resultsRoivant invested $14 million in Bayer's inhaled soluble guanylate cyclase activator mosliciguat after a $294 million biobucks agreement in 2024, and promptly advanced the candidate into a Phase 2 s…
- ADA panel still reviewing expulsions from June conference, further actions possibleThe American Diabetes Association released top‑line findings on Sept. 1 from an internal panel tasked with reviewing the June 5 expulsion of five members at its New Orleans conference. The full re…